Stockscreener 앱 받기
34.03
1.51%
-0.52
시간 외 거래:
34.03
Atricure Inc 주식(ATRC)의 최신 뉴스
Why AtriCure Inc. stock remains undervaluedWeekly Trend Report & AI Powered Market Entry Ideas - newser.com
Is AtriCure Inc. stock near bottom after decline2025 Top Gainers & Step-by-Step Trade Execution Guides - newser.com
How rising interest rates impact AtriCure Inc. stock2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
AtriCure, Inc. $ATRC Stake Raised by Nicholas Company Inc. - MarketBeat
What’s the recovery path for long term holders of AtriCure Inc.July 2025 Final Week & Growth-Oriented Investment Plans - newser.com
Is AtriCure Inc. stock overvalued by current metricsWeekly Investment Report & Precise Swing Trade Entry Alerts - newser.com
AtriCure Inc. stock trendline breakdown2025 Trading Volume Trends & Daily Growth Stock Investment Tips - newser.com
How sustainable is AtriCure Inc. stock dividend payout2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Why AtriCure Inc. stock is recommended by analysts2025 Trading Recap & Intraday High Probability Setup Alerts - newser.com
AtriCure (ATRC) Is Down 8.0% After Raising 2025 Guidance and Reporting Narrower LossesHas The Bull Case Changed? - simplywall.st
Does AtriCure Inc. qualify in momentum factor screeningTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Exit strategy if you’re trapped in AtriCure Inc.Bull Run & Stepwise Swing Trade Plans - newser.com
Intraday pattern recognizer results for AtriCure Inc.Weekly Profit Analysis & Stock Portfolio Risk Management - newser.com
AtriCure, Inc. (ATRC) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia
AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth - MSN
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
AtriCure’s BoxX-NoAF Trial: A Step Forward in Cardiac Surgery Innovation - MSN
AtriCure’s Earnings Call Highlights Robust Growth and Innovation - The Globe and Mail
AtriCure, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:ATRC) 2025-10-31 - Seeking Alpha
AtriCure’s HEAL-IST IDE Trial: A Promising Step in Treating Inappropriate Sinus Tachycardia - MSN
AtriCure (NASDAQ:ATRC) Sees Large Volume Increase on Strong Earnings - MarketBeat
AtriCure (ATRC) Losses Worsen 12.8% Annually, Challenging Bullish Profitability Narratives - Sahm
Atricure (ATRC) Gets a Buy from Canaccord Genuity - The Globe and Mail
AtriCure (ATRC) Margin Miss Challenges Hopes for Near-Term Profitability Despite Strong Growth Forecasts - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
AtriCure Inc. stock trend forecastInsider Selling & Smart Allocation Stock Tips - newser.com
Analyzing drawdowns of AtriCure Inc. with statistical toolsMarket Performance Summary & Capital Protection Trade Alerts - newser.com
Why AtriCure Inc. stock is seen as undervaluedRate Cut & AI Optimized Trading Strategy Guides - newser.com
Canaccord Genuity raises AtriCure stock price target to $64 on strong Q3 results - Investing.com Nigeria
AtriCure stock maintains Buy rating at Needham following strong Q3 results - Investing.com Nigeria
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial - MedTech Intelligence
AtriCure stock maintains Buy rating at Needham following strong Q3 results By Investing.com - Investing.com South Africa
AtriCure stock rises as Citizens reiterates Market Outperform rating after strong Q3 - Investing.com UK
Is AtriCure Inc. stock trading near support levels2025 Top Decliners & AI Driven Stock Reports - newser.com
AtriCure, Inc. Reports Strong Q3 2025 Results - The Globe and Mail
Decoding AtriCure Inc (ATRC): A Strategic SWOT Insight - GuruFocus
AtriCure (NASDAQ:ATRC) Updates FY 2025 Earnings Guidance - MarketBeat
Canaccord Genuity Maintains AtriCure (ATRC) Buy Recommendation - Nasdaq
AtriCure (NASDAQ:ATRC) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
AtriCure Inc (ATRC) Q3 2025 Earnings Call Highlights: Strong Rev - GuruFocus
AtriCure (ATRC) Q3 2025 Earnings Call Transcript - The Globe and Mail
AtriCure, Inc. SEC 10-Q Report - TradingView
[10-Q] AtriCure, Inc. Quarterly Earnings Report | ATRC SEC FilingForm 10-Q - Stock Titan
AtriCure (ATRC) Target Price Raised by Canaccord Genuity | ATRC Stock News - GuruFocus
AtriCure’s TRAC-AF Registry: A Closer Look at Ongoing Clinical Study - MSN
1.41%
0.47%
자본화:
|
볼륨(24시간):